Post

New research · Ophthalmology
Retina (Philadelphia, Pa.) · 4d
StudyRetina (Philadelphia, Pa.) · 2026

Post-Marketing Ocular Adverse Events Associated with Tamoxifen and Raloxifene: A Population-Based Pharmacovigilance Study.

Abdelrahman Abu Osba, Farah Saleh, Aaryamaan V Verma … Marko Popovic
Read paper
OphthalmologyStudy

Raloxifene strongly linked to retinal vein thrombosis in safety reports

Post-Marketing Ocular Adverse Events Associated with Tamoxifen and Raloxifene: A Population-Based Pharmacovigilance Study.

Abdelrahman Abu Osba … Marko Popovic
Retina (Philadelphia, Pa.) · 2026
Purpose

The purpose of this study was to evaluate postmarketing ocular adverse events associated with tamoxifen and raloxifene using a pharmacovigilance database.

Methods

The U.

Results
ROR 340.0
Retinal vein blood clot reports were far more common with raloxifene than other drugs
More results

There were a total of 4,084 reports of adverse events associated with tamoxifen (mean age 56.7 years), including 505 ocular adverse events.

The strongest signals were for corneal graft rejection (reporting odds ratios 118.9), retrobulbar hemorrhage (104.6), ophthalmic vein thrombosis (82.7), retinal deposits (80.7), and macular hole (78.6).

More results

Additional events included maculopathy, retinopathy, and optic neuropathy.

There were 5,600 reports of adverse events associated with raloxifene (mean age 68.6 years), including 437 ocular adverse events.

“
Conclusion · 1 of 2

Tamoxifen and raloxifene had unique ocular adverse events profiles. Tamoxifen was primarily linked to retinal, optic nerve, and corneal disorders, whereas raloxifene was strongly associated with retinal vascular and thromboembolic events.

Conclusion · 2 of 2

These findings underscore the importance of clinician awareness and future prospective studies to further elucidate the risks.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment